Using Multi-omics and Organoid Models to Find New Treatments for Metastatic Prostate Cancer

What this Trial Is About

Researchers are investigating metastatic prostate cancer mPCa, focusing especially on metastatic castration-resistant prostate cancer mCRPC. This study uses multiomics sequencing to explore molecular characteristics of these cancers and aims to identify new drug targets. The research aims to address the challenge of metastasis and drug resistance, which are major causes of death in prostate cancer patients, particularly in China where rates are rising rapidly. The study involves collecting tissue samples from patients during standard care procedures for molecular analysis. Organoid and animal models of mCRPC will be developed from these samples to serve as research platforms. These models will help study the biology of mCRPC and test potential new treatments. There is only one study group no experimental treatments are administered. Participants will provide tissue samples through surgery or biopsy and give informed consent. Researchers will analyze molecular data, develop organoid and animal models, and test responses to anti-cancer compounds. The main outcomes measured over three years include molecular features of the cancer, successful creation of organoids and animal models, and biomarker development for metastasis and drug resistance. This observational study runs until December 2028, with ongoing monitoring of samples and data.

Novel Therapy Target in Metastatic Prostate Cancer